Moderna plans to lay off 10% of workforce to cut costs
Moderna said on Thursday it would trim roughly 10 per cent of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech accelerates its cost-cutting efforts amid declining sales of COVID-19 vaccines.
The move, announced in an internal memo by CEO Stephane Bancel, is part of the company's previous plan to cut operating expenses by about US$1.5 billion by 2027.
'We've made significant progress by scaling down R&D as respiratory trials conclude, renegotiating supplier agreements, and reducing manufacturing costs,' Bancel said in the memo.
Moderna had said earlier this year it expects operating costs to be between US$4.7 billion and US$5 billion for 2027.
The Cambridge, Massachusetts-based biotech has been banking on revenue from newer mRNA shots, including its experimental COVID-flu combination vaccine, to make up for falling sales of its COVID-19 shot and less-than-expected uptake of its respiratory syncytial virus vaccine.
But investor concerns about the prospects of new shots and the changes in vaccine policy under U.S. Health Secretary and vaccine skeptic Robert F. Kennedy Jr. have led to a more than 20 per cent decline in Moderna's shares this year.
The stock, which has lost more than 90 per cent of its value since the pandemic-era highs, was trading about four per cent down on Thursday.
Moderna had said in May it did not expect regulatory approval for its combination shot until 2026, since the U.S. Food and Drug Administration asked for late-stage data showing the vaccine's efficacy against the flu.
The company had previously hoped to launch the vaccine for the autumn respiratory disease season in 2025 or 2026.
Bancel in the memo reiterated the company's target to have eight more approvals for its products in the next three years.
---
Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Bitget Hosts Crypto Experience Month 2025 Targeting Gen-Zs Across Europe, Asia and Middle East
VICTORIA, Seychelles, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bitget, the leading cryptocurrency exchange and Web3 company, officially launches Crypto Experience Month 2025, a global youth activation campaign under its Blockchain4Youth initiative. Now in its third year, the campaign takes a step away from classrooms and webinars, transforming crypto from a buzzword into something tangible, usable, and real. As part of the third-year celebration of International Youth Day in August, Bitget plans to host Crypto Experience events throughout the month of August across multiple cities in the Middle East, Europe, South East Asia, and South Asia. Crypto Experience Month 2025 is built around a simple tagline: Look What Crypto Can Do. While headlines often frame digital assets around market movements, this campaign flips the narrative, focusing instead on how blockchain is being applied in payments, gaming, DeFi, identity, and creative expression. Across pop-up activations set to roll out globally this August, Bitget is inviting young people to try crypto for themselves, not on charts, but in checkout lines, in metaverse arcades, and through everyday interactions. From university campuses to creative hubs, attendees will explore zones where they can mint NFTs, experiment with stablecoin lending, trade tokenized stocks in real-time simulations, and test drive PayFi's QR-based retail transactions. They'll receive digital badges, load up a Bitget Wallet Mastercard, and even stake assets in DeFi setups guided by in-person educators. The format is designed to merge experience with understanding, where every station is part demo, part discovery. The shift from education to interaction marks a new chapter for the campaign. Launched in 2023 with Crypto Experience Day, the campaign expanded to an entire month in 2024, reaching over 15,000 participants across 12 countries. This year's edition pushes further, prioritizing physical presence and hands-on engagement to help bridge the growing gap between Web2 curiosity and Web3 confidence. Vugar Usi Zade, Bitget's Chief Operating Officer and the executive sponsor of Blockchain4Youth, believes that relevance comes from application. 'You can't build belief in the future of crypto through theory alone. You need to let people feel it, use it, question it,' he said. 'Crypto Experience Month is about making the technology real and giving young people a reason to care about where it's going.' Bitget Wallet will serve as the official campaign partner, integrating its latest features, including PayFi, and on-chain tools into the experience zones. Jamie Elkaleh, Chief Marketing Officer at Bitget Wallet, added, 'The onboarding is just the start. It's also about showing how crypto can empower everyday actions, from payments to creativity. We're excited to bring that vision to life on the ground.' Followers of the campaign can look forward to a recap video capturing highlights from each activation in early September. Until then, Bitget's message is clear: crypto isn't just coming to the real world. It's already here, and this August, it's handing over the controls to the next generation. About Bitget Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Bitget Wallet is a leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform. Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world's most thrilling championships. Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.
Globe and Mail
2 hours ago
- Globe and Mail
GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?
Biotech bigwig Gilead Sciences, Inc. ( GILD ) is scheduled to report second-quarter 2025 results on Aug. 7, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $6.95 billion and $1.95 per share, respectively. Earnings estimate for 2025 has increased to $8.02 from $7.91 per share over the past 60 days, while that for 2026 has increased to $8.53 from $8.39 in the same timeframe. GILD's Earnings Surprise History GILD has a good track record. Its earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 16.48%. In the last reported quarter, the company's earnings missed estimates by 0.55%. What Our Model Predicts for GILD Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Earnings ESP for GILD is +0.58%. The company currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Factors Influencing GILD's Q2 Results Gilead has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy sales and Descovy for pre-exposure prophylaxis (PrEP) have fueled GILD's top-line growth in the past several quarters. HIV sales were up in the first quarter despite the impact of the new Medicare Part D model implementation due to increased demand for Biktarvy and Descovy. This trend has most likely prevailed in the second quarter as well. As per the new model, manufacturers now must provide discounts on the cost of drug for Medicare patients during the initial coverage and catastrophic phases. Secondly, the introduction of manufacturer discounts for people who qualify for the low-income subsidy program might have also had an adverse impact on HIV sales. Since this population is disproportionately affected by HIV, the HIV sales have likely been affected due to the larger cost-sharing obligations. The top-line estimate for Biktarvy and Descovy is pegged at $3.4 billion and $577 million, respectively, and our model estimate for the same is pinned at $3.4 billion and $533 million. The company recently obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. This groundbreaking injectable therapy marks the first and only twice-yearly PrEP option available in the United States. The Liver Disease portfolio includes drugs for chronic hepatitis C virus, chronic hepatitis B virus and chronic hepatitis delta virus. Higher demand for viral hepatitis medicines has likely boosted sales of this franchise in the second quarter. The FDA had earlier granted accelerated approval to seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA, under the brand name Livdelzi. The European Commission has also granted conditional marketing authorization to seladelpar for the treatment of PBC. Incremental sales from this new drug, driven by launches in additional countries, might have positively impacted the Liver Disease portfolio sales in the second quarter. Veklury sales continue to be highly variable. Cell Therapy product sales (Yescarta and Tecartus) have likely decreased in the to-be-reported quarter due to competitive headwinds, both in the United States and internationally. In particular, Tecartus sales have likely suffered due to these headwinds. The Zacks Consensus Estimate and our model estimate for Cell Therapy product sales are pinned at $490 million and $486.5 million, respectively. Trodelvy, indicated for second-line metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer, might have experienced strong demand in the second quarter even though the first-quarter sales were impacted by inventory dynamics. The Zacks Consensus Estimate and our estimate for Trodelvy sales are pinned at $324 million and $341 million, respectively. Both R&D and SG&A expenses might have decreased in the second quarter, as in the previous quarter. GILD's Price Performance and Valuation Shares of GILD have risen 22.5% year to date compared with the industry 's gain of 0.5%. The stock has outperformed the sector and the S&P 500 in this timeframe. Image Source: Zacks Investment Research Going by the price/earnings ratio, GILD's shares currently trade at 13.60x forward earnings, higher than its mean of 10.53x but lower than 14.29x for the large-cap pharma industry. Investment Thesis for GILD Gilead has a market-leading portfolio of HIV treatments. The company's consistent efforts to develop additional innovative HIV treatments are being appreciated by investors. While HIV sales might be under slight pressure in 2025, the recent approval of lenacapavir for the prevention of the disease should solidify Gilead's HIV franchise (as lenacapavir needs to be taken twice yearly unlike daily oral pills) and result in incremental sales. The approval of Livdelzi has expanded the liver-disease portfolio. Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. The uptake of Trodelvy has been good. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds (both in the United States and Europe) that are expected to continue in the rest of 2025. GILD's strategic deals and acquisitions to diversify its business are encouraging. Stay Invested in GILD Stock Gilead is one of the largest biotechs in the industry, and such large companies are generally considered safe havens for investors interested in this sector. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc ( GSK ). The company's strategic deals and acquisitions to diversify its business are encouraging. GILD has also collaborated with Merck ( MRK ) to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. However, we recommend investors to wait and watch for now as the HIV and Cell Therapy businesses navigate the expected challenges in 2025. For investors already owning the stock, staying invested would be a prudent move. The company's attractive dividend yield is a strong positive for investors. You can see . Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Globe and Mail
3 hours ago
- Globe and Mail
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance's Trader Talk with Kenny Polcari in a podcast episode titled 'AI and Biotech Take on Brain Cancer.' As Trader Talk describes it: 'When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (Nasdaq: NTHI), about how the company defied a tough market to go public, secure a $50 million partnership in the Middle East, and join the Russell Microcap Index. Heshmatpour explains NeOnc's focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC's medical school, and how global clinical trials are expanding the company's reach. The conversation also includes how AI and quantum computing could transform the biotech industry. It's a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage.' You can tune in to the episode on Apple Podcasts, Spotify, YouTube, or wherever you listen to your podcasts. ABOUT NEONC TECHNOLOGIES HOLDINGS, INC. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO ™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100 ™ and NEO212 ™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'should,' 'intend,' 'expect,' 'plan,' 'budget,' 'forecast,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'evaluating,' or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. The 'Risk Factors' section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations. 'NEO100' and NEO '212' are registered trademarks of NeOnc Technologies Holdings, Inc.
